{"title":"2010","authors":"Merritt Moseley","doi":"10.1017/9781139979672.017","DOIUrl":null,"url":null,"abstract":"This review was conducted in accordance with the statutory mandate for the Office of Inspector General (OIG) to compare average sales prices (ASP) and average manufacturer prices (AMP) for Medicare Part B prescription drugs and identify ASPs that exceed AMPs by at least 5 percent. The review also estimated the financial impact of lowering reimbursement amounts for drugs that exceeded the 5-percent threshold to 103 percent of the AMP, pursuant to statute.","PeriodicalId":356494,"journal":{"name":"Los 25 años de la OMC: Una retrospectiva fotográfica","volume":"25 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"2010\",\"authors\":\"Merritt Moseley\",\"doi\":\"10.1017/9781139979672.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This review was conducted in accordance with the statutory mandate for the Office of Inspector General (OIG) to compare average sales prices (ASP) and average manufacturer prices (AMP) for Medicare Part B prescription drugs and identify ASPs that exceed AMPs by at least 5 percent. The review also estimated the financial impact of lowering reimbursement amounts for drugs that exceeded the 5-percent threshold to 103 percent of the AMP, pursuant to statute.\",\"PeriodicalId\":356494,\"journal\":{\"name\":\"Los 25 años de la OMC: Una retrospectiva fotográfica\",\"volume\":\"25 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Los 25 años de la OMC: Una retrospectiva fotográfica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1017/9781139979672.017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Los 25 años de la OMC: Una retrospectiva fotográfica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/9781139979672.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
This review was conducted in accordance with the statutory mandate for the Office of Inspector General (OIG) to compare average sales prices (ASP) and average manufacturer prices (AMP) for Medicare Part B prescription drugs and identify ASPs that exceed AMPs by at least 5 percent. The review also estimated the financial impact of lowering reimbursement amounts for drugs that exceeded the 5-percent threshold to 103 percent of the AMP, pursuant to statute.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
